Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer

Inclusion Criteria

• •Patients must be ≥18 years.
• •Provision of fully informed consent prior to any study specific procedures.
• •Patients with extensive stage SCLC diagnosed by pathology (as staged by the American Veterans Lung Cancer Association (VALG)), who do not have an imaging response during first-line treatment with PD-(L)1 inhibitors, or who progress after imaging reactions on first-line therapy (the most recent regimen prior to enrollment must contain PD-(L)1 inhibitors).
• •According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.